Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3593309 | 0.90 | L3MBTL3 (0.33) | L3MBTL3L3MBTL1ALDH1A1KDM4ETDP1 | |
| SCHEMBL737435 | 0.83 | L3MBTL3 (0.39) | L3MBTL3L3MBTL1 | |
| SCHEMBL735624 | 0.81 | L3MBTL3 (0.38) | L3MBTL3L3MBTL1 | |
| SCHEMBL736517 | 0.81 | L3MBTL3 (0.38) | L3MBTL3L3MBTL1 | |
| SCHEMBL736038 | 0.81 | L3MBTL3 (0.38) | L3MBTL3L3MBTL1 | |
| SCHEMBL302125 | 0.79 | L3MBTL1 (0.38) | L3MBTL3L3MBTL1ALDH1A1KDM4ETDP1 | |
| SCHEMBL3585321 | 0.78 | KDM4E (0.33) | L3MBTL3L3MBTL1ALDH1A1LMNATP53 | |
| SCHEMBL21724211 | 0.77 | L3MBTL3 (0.39) | L3MBTL3L3MBTL1ALDH1A1KDM4ETDP1 | |
| SCHEMBL737575 | 0.76 | SMN1; SMN2 (0.43) | L3MBTL3L3MBTL1ALDH1A1KDM4EHRH3 | |
| SCHEMBL81246 | 0.75 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1ALDH1A1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103003253-A | Acid addition salts of the 2-[2-[[(4-methoxy-2,6-dimethylphenyl) sulfonyl]-(methyl)amino]ethoxy]-n-methyl-n-[3- (4-methylpiperazin-1-yl)cyclohexyl] acetamide and the use thereof as bradykinin b1 receptor antagonists | BOEHRINGER INGELHEIM INT | 2013-03-27 | — | — | CN | claimed |
| CN-103003253-A | Acid addition salts of the 2-[2-[[(4-methoxy-2,6-dimethylphenyl) sulfonyl]-(methyl)amino]ethoxy]-n-methyl-n-[3- (4-methylpiperazin-1-yl)cyclohexyl] acetamide and the use thereof as bradykinin b1 receptor antagonists | BOEHRINGER INGELHEIM INT | 2013-03-27 | — | — | CN | disclosed |
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | L3MBTL3 2360/4885L3MBTL1 1749/4885ALDH1A1 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.